Bococizumab is a novel anti-PCSK9 antibody effectively developed to address hypercholesterolemia. It therapeutic agent works by the PCSK9 protein, a essential regulator of cholesterol levels. By blocking the activity https://www.targetmol.com/compound/bococizumab